Boya Bio-Pharmaceutical Group Co.Ltd(300294) : special report on the deposit and use of raised funds in 2021

Boya Bio-Pharmaceutical Group Co.Ltd(300294)

Special report on the deposit and use of raised funds in 2021

Boya Bio-Pharmaceutical Group Co.Ltd(300294) (hereinafter referred to as “the company” or “the company”) the board of directors in accordance with the guidelines for self discipline supervision of listed companies on Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM, the announcement form of information disclosure of listed companies on Shenzhen Stock Exchange No. 21: Special report form on the annual deposit and use of raised funds by listed companies According to the requirements of gem information disclosure business Memorandum No. 1 – use of over raised funds and idle raised funds, the “special report on the storage and use of raised funds in 2021” has been prepared as of December 31, 2021. The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.

Part I funds raised by non-public offering in 2018

1、 Basic information of funds raised by non-public offering in 2018

(I) actual amount of raised funds and receipt of funds

According to the resolution of the company’s second extraordinary general meeting in 2017 and the reply on approving Boya Bio-Pharmaceutical Group Co.Ltd(300294) non-public development of shares (zjxk [2018] No. 117) issued by China Securities Regulatory Commission, the company’s non-public offering of no more than 37.5 million shares is approved. On April 4, 2018, the company completed this non-public offering and actually issued 32247662 shares at an issue price of 31.01 yuan per share. On April 4, 2018, the company received 999999999862 yuan of the subscribed purchase amount of the investor remitted by China Greatwall Securities Co.Ltd(002939) and deducted 850000000 yuan of underwriting and recommendation expenses, of which 7914999862 yuan was deposited into the bank deposit account opened by the company in China Citic Bank Corporation Limited(601998) Nanchang Branch (Account No.: 811570113100148137), Deposit 20000000000 yuan into the bank deposit account opened by the company in Industrial And Commercial Bank Of China Limited(601398) Fuzhou branch (Account No.: 151120092910050264). In addition, after deducting 224400000 yuan of issuance expenses paid and unpaid by the company in the early stage, the net amount of funds raised from non-public offering of shares is 98925599862 yuan.

The availability of the above raised funds has been verified by Jiangsu notary Tianye Certified Public Accountants (special general partnership), and the capital verification report (Sugong w [2018] No. b041) has been issued.

(II) use and balance of raised funds

In 2021, the total amount of raised funds used was 72000000 yuan, and the cumulative total amount of raised funds used was 2944831348 yuan; As of December 31, 2021, the balance of the special account for raised funds was 9607506046 yuan. The specific use of the raised funds is as follows:

Monetary unit: RMB

Cumulative amount of the project (yuan)

1、 Net proceeds 98925599862

Plus: interest income from raised funds in previous years minus handling charges 3335378113

The interest income of raised funds in this year minus the handling fee of 291359419

2、 Use of supporting raised funds 92944831348

Including: 1 Replaced 1155917317 of the raised funds invested by the company in advance with self raised funds before the raised funds were in place

2. After the raised funds are in place, the raised funds for the project will be 1788914031

3. Use idle raised funds to invest in financial management projects of 900000000000

3、 The balance of unused supporting raised funds is 9607506046

4、 The actual balance of the special account for supporting raised funds is 9607506046

5、 Difference-

2、 Deposit and management of raised funds

(I) management of raised funds

In order to standardize the management and application of the company’s raised funds and protect the interests of investors, the company is in accordance with the company law of the people’s Republic of China

Securities Law of the people’s Republic of China, Shenzhen Stock Exchange GEM Listing Rules, Shenzhen Stock Exchange listed companies self regulatory

Regulatory guidelines No. 2 – standardized operation of companies listed on GEM and Boya Bio-Pharmaceutical Group Co.Ltd(300294) articles of association have been formulated

The Boya Bio-Pharmaceutical Group Co.Ltd(300294) raised funds management system is responsible for the storage, use and collection of raised funds in the special account for raised funds

Detailed and strict provisions have been made on the change of capital investment projects, the management and supervision of raised funds and information disclosure.

In order to standardize the management of the company’s raised funds and protect the rights and interests of small and medium-sized investors, according to relevant laws and regulations and Shenzhen Stock Exchange

Guidelines for self discipline supervision of listed companies on the stock exchange No. 2 – standardized operation of companies listed on the gem, the company and the sponsor

Securities Co., Ltd. signed with China Citic Bank Corporation Limited(601998) Nanchang branch and Industrial And Commercial Bank Of China Limited(601398) Fuzhou branch respectively

Tripartite supervision agreement on raised funds

(II) storage of raised funds in special account

As of December 31, 2021, the balance of the special account for raising funds of the company totaled 9607506046 yuan. The specific details of the account are as follows:

Below:

Monetary unit: RMB

Deposit bank account number amount storage form

China Citic Bank Corporation Limited(601998) Nanchang Branch 8115701131001481374748490345 current account

Industrial And Commercial Bank Of China Limited(601398) Fuzhou branch 1511200929100502644859015701 current account

Total 9607506046

3、 Comparison of use of raised funds

As of December 31, 2021, the actual use of the company’s raised funds was 294483 million yuan, as shown in the table below:

Monetary unit: RMB 10000

The total amount of raised funds (after deducting the issuance expenses) is 9892560. The total amount of raised funds invested in this year is 72.00. The total amount of raised funds with changed purposes during the reporting period is 0.00

The accumulated total amount of raised funds for changing purposes is 0.00, the accumulated total amount of raised funds invested is 294483, and the proportion of the accumulated total amount of raised funds for changing purposes is 0.00%

Whether the project is up to date, the project can be changed, and the investment after adjustment is up to the end of the period. Whether the cumulative investment of the current year is up to the expected feasibility is the investment change of the raised funds, and the progress of the total investment amount of the current year is borne by the raised funds (3) The availability can be realized to the expected non occurrence of the project (including the total investment (1) amount (2) = the significant change of income and benefit on the status date (2) / (1) period benefit

(change)

Committed investment projects

Kiloton blood system

Product intelligence factory no 98925609892560 72.00294483 2.98% – no

Construction Project

Committed investment – 98925609892560 72.00294483 2.98% -————

Inapplicability of the sub total failing to reach the planned progress or expected income and reasons (by specific project) major changes in the feasibility of the project inapplicability description of the amount, purpose and use progress of the over raised funds inapplicability of the implementation of the investment project with raised funds change of location inapplicability of the implementation of the investment project with raised funds adjustment of mode inapplicability

In order to speed up the implementation of the company’s investment projects with raised funds, the company has used self raised funds to make early investment in relevant investment projects with raised funds before the funds are actually in place. As of April 9, 2018, the accumulated amount of the raised funds invested by the company in advance with self raised funds is 1155917317 yuan, including 425000000 yuan for the advance land of the thousand ton blood products intelligent factory construction project, 657057017 yuan for process design, and 73860300 yuan for survey, design, consultation, evaluation and other expenses. The 16th meeting of the 6th board of directors and the 13th meeting of the 6th board of supervisors deliberated and adopted the proposal on using raised funds to replace self raised funds invested in advance. The board of supervisors and independent directors of the company issued explicit consent opinions, and the company’s audit institution Jiangsu notarial Tianye Certified Public Accountants (special general partnership) conducted a special audit, And issued the assurance report on pre investment of raised investment projects with self raised funds (Su Gong w [2018] No. e1242).

The 21st Meeting of the 6th board of directors held on November 26, 2018 deliberated and adopted the regulation on the use of part of idle raised funds